Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

Reverse Rett

Research | Advocate | Cure

Report and financial statements for the year ended 31 December 2025

Registered charity in England & Wales (1136809) and in Scotland (SC046735)
Registered in England & Wales Company number: 07278507

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

Reverse Rett
Reference and Administrative details
For the year ended 31st December 2025

Company number 07278507
Charity number 1136809 in England and Wales, SC046735 in Scotland
Registered office and operational address
Reverse Rett, Beehive Mill, Jersey Street, Manchester, M4 6JG

Trustees:
Trustees, who are also directors under company law, who served during the year and up to the date of this report were as follows:

John Harald Sharpe	Chair
Helen Kay Simmonds	Vice Chair
Rachael Emma Stevenson*	
Andrew John Stevenson*	
Michael Christopher Jones	
Dr Ruksana Ahmed	*resigned 22.04.25
Joanna K L Snyder	
Kate McMaster	
Catherine McKinney	
Ortensia Martinotti	*resigned 22.04.25
Jocelyn LeBlanc Ph.D	
Oliver Freeman	
Matthew Billingsley	

*Trustees who are also Directors of the charitable company. The current number of guarantee members is 11.

Trustees who held title to property belonging to the charity during the reporting period or at the date of approval were: NA

Key management personnel	Chief Executive	Rachael Stevenson
	Operations Manager	Catherine Sim

Bankers Barclays Bank UK PLC, Leicester, LE87 2BB

Auditors Slade & Cooper Limited Beehive Mill, Jersey Street, Manchester, M4 6JG

The trustees present their report and the audited/unaudited financial statements for the year ended 2025.

Included within the trustees' report is the directors' report as required by company law. Reference and administrative information set out on page 1 forms part of this report. The financial statements comply with current statutory requirements, the memorandum and articles of association and the Statement of Recommended Practice - Accounting and Reporting by Charities: SORP applicable to charities preparing their accounts in accordance with FRS 10

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

Objectives and Activities

Objectives and Activities

Mission

Reverse Rett is a patient advocacy and research organisation focused on delivering treatments and ultimately a cure for Rett syndrome and related MECP2 disorders.

Charity Objectives

The charity's objectives are to:

- Fund laboratory and clinical research projects.
- Advocate for access to treatments and therapies.
- Disseminate research and health information.
- Raise public awareness of Rett syndrome and MECP2 disorders.
- Support individuals and families affected by Rett syndrome and related disorders.

The trustees review the aims, objectives and activities of the charity each year. This report looks at what the charity has achieved and the outcomes of its work in the reporting period. The trustees report the success of each key activity and the benefits the charity has brought to those groups of people that it is set up to help. The review also helps the trustees ensure the charity's aims, objectives and activities remained focused on its stated purposes.

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning its future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives that have been set.

Activities and Achievements During 2025

Preparing the UK for Treatments

Throughout 2025, Reverse Rett continued its core mission of ensuring that children, young people and adults with Rett syndrome in the UK are ready to benefit from emerging treatments as they become available.

The charity continued to work closely with researchers, regulators, clinicians, industry partners and patient communities to reduce barriers to treatment access and improve clinical readiness.

The Board believes that 2025 represented a significant step forward in preparing the UK Rett community for the transition from research to treatment.

Rett Registry UK

Rett Registry UK remains one of Reverse Rett's most important strategic assets.
Originally established in 2014 to support clinical trial readiness, the Registry continued to expand throughout 2025 and now contains information on 813 individuals affected by Rett syndrome and related disorders. During 2025 a further 101 individuals joined the Registry, following growth of 94 participants during 2024.

The Registry underwent substantial development work during the year, including redesign as an independently hosted application. These improvements enhanced security, usability and patient control over personal data whilst supporting more efficient recruitment into

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

future clinical trials and observational research studies.

The Board believes the Registry will play an increasingly important role as gene therapy and disease-modifying treatments progress through clinical development.

Clinical Trial Readiness and Industry Engagement

Reverse Rett continued to support industry partners developing treatments for Rett syndrome and related disorders.

The charity worked closely with pharmaceutical companies, clinicians and researchers to assist with community engagement, patient communication, burden-of-illness studies, regulatory preparation and clinical trial readiness activities.

The charity maintained its commitment to ensuring equitable access to future treatments for all individuals with Rett syndrome regardless of age, gender or location.

Supporting Research

UK Research

Reverse Rett remains committed to supporting high-quality UK research.

All research funding decisions continue to be subject to independent peer review in accordance with the standards required by the Association of Medical Research Charities (AMRC).

During the period, restricted funding remained available for the Singh Research Project and other future UK research initiatives.

MECP2 Duplication Syndrome

The charity continued to support the UK MECP2 Duplication Syndrome community as part of the organisation’s remit to develop treatments for Rett syndrome and related MECP2 disorders. Funds raised specifically by families affected by MECP2 Duplication Syndrome remain ring-fenced and are dedicated exclusively to projects supporting research and treatment development for the condition.

Improving Health Outcomes

Cost of Illness Project

One of the most significant developments during 2025 was the advancement of major work towards the UK's first Rett syndrome Cost of Illness Model.

Developed in partnership with Costello Medical, this project aims to provide robust evidence demonstrating the substantial impact of Rett syndrome on individuals, families, health services and society.

The Board believes this work will be critical in supporting future Health Technology Assessments and reimbursement decisions as treatments become available.

Health Milestones Programme

During 2025 the charity implemented a new annual project, the Health Milestones Programme. This initiative was designed to improve understanding of health outcomes across the lifespan in Rett syndrome. It also provides families with essential insights into risk factors which may be mitigated by further clinical intervention. Reverse Rett also

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

provided direct support to families where appropriate, helping them to secure referrals for appropriate services as needed.

This work forms part of Reverse Rett's wider commitment to generating evidence that supports improved clinical care and better long-term outcomes.

Mortality Research

The charity also initiated work relating to mortality in Rett syndrome. A nationwide mortality survey was developed to improve understanding of mortality in UK patients and associated risk factors, with the aim of informing future healthcare policy, clinical practice and resource allocation.

Emergency Alert Card

Learnings from the UK Rett syndrome Mortality Survey informed the development of the Rett Syndrome Emergency Alert Card during 2025. This card was sent to every registered UK patient to support family/carer advocacy for patients with Rett in emergency situations. The card is designed to help healthcare professionals rapidly identify key clinical risks and considerations associated with Rett syndrome and improve decision-making during acute illness or injury.

Supporting Families and Professionals

LEAP Conference

The annual LEAP Conference remains the charity's flagship educational event.

The 2025 conference brought together families, clinicians, researchers, industry representatives and allied health professionals to share knowledge, discuss emerging treatments and improve understanding of the challenges associated with Rett syndrome.

The conference continues to provide an important opportunity for the community to learn directly from experts whilst strengthening connections between families and professionals.

Reverse Rett Bitesize

The charity continued to deliver its highly successful Reverse Rett Bitesize online education programme.
Sessions focused on topics including:

- The Art of Fundraising with Head of Fundraising, Andy Stevenson
- Rett syndrome from Genes to Symptoms with Prof Santosh and Dr Singh.
- Rett syndrome: Ask Dr Dan with Dr Daniel Lumsden.
- Health Milestone Matter: Insights for Families Living with Rett syndrome with CEO, Rachael Stevenson and Operations Manager, Catherine Sim

These sessions enable families to access high-quality educational content regardless of geographical location and continue to achieve strong levels of engagement.

Community Support Networks

Reverse Rett continued to facilitate extensive peer support networks throughout 2025.
These included:

- The Reverse Rett Community Facebook Group.
- Parent-to-parent support.

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

- Approximately twenty special interest WhatsApp support groups.
- Online educational workshops and webinars.
- Individual What's App groups for family members and staff to have direct contact re individual patients.

The Board recognises the importance of these networks in reducing isolation and improving access to information for families affected by Rett syndrome.

Clinical Care Support

CIPP Rett Centre

For six years Reverse Rett has provided substantial funding to support the CIPP Rett Centre at King's College London.

During this time the Centre has provided specialist care for more than 200 patients with Rett syndrome and has played a critical role in advancing clinical understanding and patient management in the UK.

Following a planned reduction in funding during 2024, Reverse Rett completed its commitment to funding the Centre during 2025.

This milestone reflects the charity's intention to transition from directly funding clinical services towards supporting sustainable NHS-led provision wherever possible whilst maintaining its focus on treatment access, research and advocacy.

Membership and Credibility

Reverse Rett remains a full member of the Association of Medical Research Charities (AMRC).

Membership demonstrates the charity's commitment to transparency, accountability and excellence in research funding. All research projects supported by the charity continue to be assessed through independent peer-review processes consistent with AMRC requirements.

The charity also maintains productive relationships with:

- Rett Syndrome Research Trust (USA).
- Opé Rett.
- Rett Syndrome Ireland.
- Gudrun's Rett Syndrome Research Trust.
- Israel Rett Syndrome Research and Treatment Foundation.

The charity continued to work closely with industry partners including but not limited to Neurogene and Taysha Gene Therapies.

Financial Review

Financial Performance

2025 represented a transformational year for Reverse Rett's finances.
Total income increased to **£875,782** (2024: £809,095), whilst expenditure reduced significantly to **£677,452** (2024: £810,763) as part of the charity's planned reduction in funding of the CIPP Rett Centre.

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

As a result, the charity generated a surplus of **£198,330** compared with a deficit of £1,668 in 2024.
The improvement reflects:

- Successful completion of major funding commitments.
- Growth in fundraising income.
- Strong external event performance.
- Improved operational efficiency.
- Continued support from the Rett community and external funders.

Income

Income was generated from a diverse range of sources.
Key income streams included:

- Donations and legacies: £464,986.
- Events and fundraising activities: £157,544.
- Glasgow Gala income: £76,879.
- Big Give Christmas Challenge: £87,682.
- Gift Aid: £72,370.
- 365 Club: £15,700.

The Board remains grateful to all families, supporters, corporate partners, trusts and foundations whose generosity makes the charity's work possible.

Expenditure

Total expenditure during the year was £677,452.
Significant expenditure included:

- Fundraising costs: £368,102.
- Charitable activities: £299,332.
- King's College London/CIPP Rett Centre funding: £112,139.
- Clinical and research programmes. £29800.
- Registry development. £1246.44
- Educational activities.
- Advocacy and community support.

2025 was a transformational year for Reverse Rett. After several years of funding intensive clinical infrastructure and navigating post-pandemic challenges, the charity returned to a substantial surplus while simultaneously expanding its research, advocacy and family support activities. Throughout the year we focused on preparing the UK Rett community for the arrival of treatments, strengthening the evidence base needed for future access decisions, and ensuring that every person living with Rett syndrome has the opportunity to benefit from advances in science**.**

Reserves Policy

The trustees aim to maintain reserves equivalent to approximately three to six months of operating expenditure.
31 December 2025:

- Total funds stood at £100,705.
- Restricted funds were £50,566.
- Unrestricted funds were £50,139.

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

- Cash at bank and in hand was £86,984.

The trustees recognise that unrestricted reserves remain limited but are encouraged by the substantial improvement in the charity's financial position and expect further strengthening during 2026.

Fundraising Statement
Reverse Rett's fundraising activities are primarily undertaken by families, friends and supporters of individuals affected by Rett syndrome and MECP2 Duplication Syndrome.
The charity does not employ professional fundraising agencies and does not undertake cold-calling, street fundraising or unsolicited direct marketing.
Reverse Rett is registered with the Fundraising Regulator and complies with the Code of Fundraising Practice.
During 2025:

- No professional fundraisers were engaged.
- Fundraising activity was monitored directly by staff and trustees.
- No complaints were received regarding fundraising activity.
- The charity remained compliant with its fundraising policies and procedures.

The trustees are grateful to all supporters who participated in fundraising events, challenge activities, gala events, community campaigns and the Big Give Christmas Challenge.

Strategic Direction

During 2025 the trustees finalised development of a new ten-year strategy covering the period 2026–2036.

The strategy builds upon the charity's achievements over the previous decade and focuses on accelerating treatment access, improving health outcomes and strengthening support for individuals and families affected by Rett syndrome.

The Board believes the charity is entering a period of significant opportunity as scientific progress increasingly moves towards clinical implementation.

Plans for 2026

Key priorities for 2026 include:

- Continued expansion of Rett Registry UK.
- Publication and utilisation of the UK Cost of Illness Model.
- Development of mortality and health outcomes research.
- Expansion of advocacy activities.
- Delivery of LEAP and Bitesize education programmes.
- Support for emerging gene therapy and clinical trial programmes.
- Continued growth of fundraising and unrestricted income.
- Initial implementation of the 2026–2036 strategic plan.
- Strengthening organisational resilience and reserves.

The trustees remain optimistic that advances in research, combined with growing understanding of disease burden and patient outcomes, will help bring meaningful treatments closer to reality for everyone affected by Rett syndrome.

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

Acknowledgements

The trustees would like to thank:

- Our children, young people and adults living with Rett syndrome and related disorders.
- Families, carers and supporters.
- Regional Ambassadors and community volunteers.
- Corporate partners, trusts and foundations.
- Researchers, clinicians and healthcare professionals.
- Industry partners.
- Reverse Rett staff and trustees.

Their dedication, generosity and determination continue to drive progress towards treatments and ultimately a cure for this devastating condition.

Structure, governance and management

Reverse Rett is a company limited by guarantee, company number 07278507 incorporated on 9th June 2010. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its articles of association.

Reverse Rett is a charity registered in England and Wales, charity number 1136809 and a charity registered in Scotland, charity number SC046735.

The first Trustees are those persons notified to Companies House as the first Directors of the Charity. The Charity may by ordinary resolution, appoint a person who is willing to act as a Director and determine the length of rotation in which any additional directors are to retire.

Rachael Stevenson and Andrew Stevenson were involved in the founding of the Charity and remain Trustees to date.

The management of the company is the responsibility of the Trustees who are elected and co-opted under the terms of the Articles of Association.

The trustees are members of the charity, but this entitles them only to voting rights. The trustees have no beneficial interest in the charity.

Members of the charity guarantee to contribute an amount not exceeding £1 to the assets of the charity in the event of winding up. The total number of such guarantees on 31 December 2025 was 11.

The Trustees of the Charity who served during the year ended December 31, 2025 are shown on p1.

The Trustees generally meet in person, once annually and via online conferencing on a bi-monthly basis and as needed basis.

As a parent-driven, patient organisation, Reverse Rett looks first to the Rett Syndrome community to recruit Trustees. The organisation’s founding document states in section 19 that

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

- *A Director must be a natural person aged 16 years or older.*

- *No one may be appointed a Director if he or she would be disqualified from acting under the provisions of article 21.*

No other person or external body is permitted to appoint charity trustees.

Induction and training of Trustees is delivered in person through one-to-one contact with the organisation's Chairman, where Trustee's roles and responsibilities are explained and supporting information is sent to the newly recruited Trustee as appropriate.

Reverse Rett is a full member of the umbrella organisation, the Association of Medical Research Charities (AMRC). Membership of AMRC requires member organisations to fulfil specific criteria with regards to a high standard of external peer review of proposed research projects and subsequent monitoring.

Detailed information about the established AMRC peer review process at Reverse Rett can be found here.

The Board of Trustees of Reverse Rett delegates day to day operational responsibility of the organisation to the CEO, Rachael Stevenson.

In accordance with the charity's Financial Procedures Policy, expenditure of >£20K must be approved by Board Chairman as well as CEO.

The Board of Trustees must review and approve:

- New organisation policies
- Amendments to existing policies
- Funding of new research projects

- Salary increases for CEO and related parties
- Remuneration policy for key management personnel

The Reverse Rett Conflict of Interest Policy is signed annually by all Trustees.

Two of the charity's Trustees are full-time employees of the organisation and thus receive a salary for their work. These salaries are highlighted under **Trustee remuneration and expenses, and related party transactions** due to AS and RES Trustee status.

These figures reflect **salary only** and are not additional expenses recovered by AS and RES in relation to their employment at Reverse Rett.

As Founding Trustees of the organisation, Rachael Stevenson and Andrew Stevenson are recused from any Board meetings to discuss the details of their employment at Reverse Rett. Adjustments in remuneration for both parties are decided by the Board of Trustees.

Employment of Directors of the Charity is permitted by Article 6.4.2 of the Memorandum and Articles of Association of the Charity which provides that Directors of the Charity may be employed providing that the majority of Directors do not benefit in this way.

All remaining trustees give their time voluntarily and receive no benefits from the charity. Any expenses reclaimed from the charity by these Trustees are detailed below under **Trustee remuneration and expenses, and related party transactions.**

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

Related parties and relationships with other organisations

Reverse Rett is a full member of the Association of Medical Research Charities (AMRC) We work in partnership with the following organisations:

- Rett Syndrome Research Trust (USA)
- Opé Rett
- Gudrun's Rett Syndrome Research Trust
- Israel Rett Syndrome Research and Treatment Foundation
- Rett Syndrome Ireland

With special thanks to our industry partners:

- Acadia
- Anavex Life Sciences Corp.
- Neurogene Inc.
- Taysha Gene Therapies

Risk Management

At the 2024 annual in-person meeting, trustees reviewed key risks, including:

1. **Sudden drop in fundraising** – mitigated by a six-month reserve policy
2. **Key personnel changes** – especially as two senior staff are related and parents of children with Rett Syndrome

To reduce risk, an **Operations Manager** was appointed in 2023, easing workload and improving continuity. The charity also holds **key personnel insurance** for the CEO.

Trustee Recruitment and Board Composition

Proposed trustees are invited to attend a board meeting to introduce themselves, after which a vote is held. In 2022, the Trustees prioritised diversifying the Board by recruiting members not directly affected by Rett Syndrome. As of July 2025, **9 of Trustees** are personally affected, compared to **8 in July 2023**.

Remuneration and Related Party Transactions

Two Trustees, **Rachael Stevenson** and **Andrew Stevenson**, are full-time employees. As Founding Trustees, they are recused from decisions relating to their employment. Salary adjustments are made by the remaining Board members.

Employment of Trustees is permitted under **Article 6.4.2** of the charity's Articles of Association, provided the majority of trustees do not receive financial benefit.

All other Trustees serve voluntarily and receive no remuneration. Reimbursed expenses (if any) are disclosed in **Note 10** of the accounts.

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

Statement of responsibilities of the trustees

The trustees (who are also directors of Reverse Rett for the purposes of company law) are responsible for preparing the trustees' annual report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- Select suitable accounting policies and then apply them consistently
- Observe the methods and principles in the Charities SORP
- Make judgements and estimates that are reasonable and prudent
- State whether applicable UK Accounting Standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- There is no relevant audit information of which the charitable company's auditors are unaware
- The trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

The trustees' annual report has been approved by the trustees on 09/09/2026 and signed on their behalf by

Signed by:
John Sharpe
71B5BE390D6444F...
John Sharpe
Chair of Trustees

DocuSigned by:
Rachael Stevenson
31DCB110517845B...
Rachael Stevenson CEO
Chief Executive Office and Trustee

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

Independent Auditors' Report to the Members and Trustees of Reverse Rett

Opinion

We have audited the financial statements of Reverse Rett (the 'charitable company') for the year ended 31 December 2025, which comprise the Statement of Financial Activities (including the income and expenditure account), the Balance Sheet, the Statement of Cash Flows and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2025, and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the trustees' annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report (incorporating the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception
In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies' regime and take advantage of the small companies' exemptions in preparing the Trustees' Annual Report and from the requirement to prepare a strategic report.

Responsibilities of trustees
As explained more fully in the trustees' responsibilities statement set out on page 11, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The specific

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud is detailed below:

- enquiry of management and those charged with governance around actual and potential litigation and claims.
- enquiry of the charity's staff, management and those charged with governance to identify any instances of non-compliance with laws and regulations.
- reviewing minutes of meetings of those charged with governance.
- reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations.
- auditing the risk of management override of controls, including through testing journal entries and other adjustments for appropriateness, and evaluating the business rationale of significant transactions outside the normal course of business.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council's website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Chinwe Jennifer Daniel FCCA DChA
Senior Statutory Auditor
for and on behalf of
Slade & Cooper Limited
Statutory Auditors
Beehive Mill
Jersey Street
Manchester, M4 6JG

Date: ___/__/2026

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

Reverse Rett

Statement of Financial Activities
(including Income and Expenditure account)
for the year ended 31 December 2025

	Note	Unrestricted funds £	Restricted funds £	Total funds 2025 £	*Total funds 2024 £*
Income from:					
Donations and legacies	3	387,486	77,500	464,986	*517,181*
Charitable activities:	4	410,796	-	410,796	*291,914*
Total income		**798,282**	**77,500**	**875,782**	***809,095***
Expenditure on:					
Raising funds	5	256,685	111,417	368,102	*297,979*
Charitable activities:	6	307,634	1,716	309,350	*512,784*
Total expenditure		**564,319**	**113,133**	**677,452**	***810,763***
Net income / (expenditure) for the year	8	**233,963**	**(35,633)**	**198,330**	***(1,668)***
Transfer between funds		-	-	-	-
Net movement in funds for the year		**233,963**	**(35,633)**	**198,330**	***(1,668)***
Reconciliation of funds					
Total funds brought forward		(183,824)	86,199	(97,625)	*(95,957)*
Total funds carried forward		**50,139**	**50,566**	**100,705**	***(97,625)***

The statement of financial activities includes all gains and losses recognised in the year.
All income and expenditure derive from continuing activities.

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

Reverse Rett
Company number 07278507

Balance sheet as at 31 December 2025

	Note	2025 £	2025 £	*2024 £*	*2024 £*
Fixed assets					
Tangible assets	12		1,207		*2,415*
Total fixed assets			**1,207**		***2,415***
Current assets					
Debtors	13	222,075		*96,404*	
Cash at bank and in hand		86,984		*64,496*	
Total current assets		**309,059**		***160,900***	
Liabilities					
Creditors: amounts falling due in less than one year	14	(209,561)		*(260,940)*	
Net assets			**100,705**		***(97,625)***
The funds of the charity:					
Restricted income funds	15		50,566		*86,199*
Unrestricted income funds	16		50,139		*(183,824)*
Total charity funds			**100,705**		***(97,625)***

These accounts are prepared in accordance with the special provisions of part 15 of the Companies Act 2006 relating to small companies and constitute the annual accounts required by the Companies Act 2006 and are for circulation to members of the company.

The notes on pages 18 to 33 form part of these accounts.

Approved by the trustees on 09/09/2026 and signed on their behalf by:

Signed by:
John Sharpe
71B5BE390D6444F...

John H Sharpe (Chair)

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

Reverse Rett

Statement of Cash Flows
for the year ending 31 December 2025

	Note	2025 £	*2024* *£*
Cash provided by / (used in) operating activities	18	**22,488**	***19,672***
Cash flows from investing activities:			
Purchase of tangible fixed assets		-	*(1,551)*
Cash provided by / (used in) investing activities		**-**	***(1,551)***
Increase/(decrease) in cash and cash equivalents in the year		22,488	*18,121*
Cash and cash equivalents at the beginning of the year		64,496	*46,375*
Cash and cash equivalents at the end of the year		**86,984**	***64,496***

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

1 Accounting policies

The principal accounting policies adopted, judgments and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

a Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), second edition - October 2019 (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006 and UK Generally Accepted Accounting Practice.

Reverse Rett meets the definition of a public benefit entity under FRS102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note.

b Preparation of the accounts on a going concern basis

The trustees consider that there are no material uncertainties about the charitable company's ability to continue as a going concern.

The trustees have made no key judgments which have a significant effect on the accounts.

The trustees do not consider that there are any sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities within the next reporting period.

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

c Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the charity that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is a treated as a contingent asset and disclosed if material.

Income received in advance of a provision of a specified service is deferred until the criteria for income recognition are met.

d Donated services and facilities

Donated professional services and donated facilities are recognised as income when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), general volunteer time is not recognised; refer to the trustees' annual report for more information about their contribution.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

e Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the Bank.

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

f Fund accounting

Unrestricted funds are available to spend on activities that further any of the purposes of charity.

Designated funds are unrestricted funds of the charity which the trustees have decided at their discretion to set aside to use for a specific purpose.

Restricted funds are donations which the donor has specified are to be solely used for particular areas of the charity's work or for specific projects being undertaken by the charity.

g Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

h Allocation of support costs

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include back office costs, finance, personnel, payroll and governance costs which support the charity's programmes and activities.

i Operating leases

Operating leases are leases in which the title to the assets, and the risks and rewards of ownership, remain with the lessor. Rental charges are charged on a straight line basis over the term of the lease.

j Tangible fixed assets

Individual fixed assets costing £1,000 or more are capitalised at cost and are depreciated over their estimated useful economic lives on a straight line basis as follows:

Office equipment	25%
Computer equipment	25%

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

k Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

l Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

m Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

n Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

o Pensions

Employees of the charity are entitled to join a defined contribution ‘money purchase’ scheme. The charity’s contribution is restricted to the contributions disclosed in note 9. There were no outstanding contributions at the year end.

2 Legal status of the charity

The charity is a company limited by guarantee registered in England and Wales and has no share capital. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity. The registered office address is disclosed on page 1.

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

3 Income from donations and legacies

	Unrestricted £	Restricted £	Total 2025 £
Donations	365,667	-	365,667
Grants			
Reverse Rett LEAP day			
- Acadia Pharmaceuticals	-	7,500	7,500
- Neurogene Inc.	-	30,000	30,000
- Taysha Gene Therapies Inc.	-	20,000	20,000
The Fitton Trust	-	20,000	20,000
Other grants	21,000	-	21,000
Legacies	819	-	819
Total	387,486	77,500	464,986

Income from donations and legacies - previous year

	Unrestricted £	*Restricted £*	*Total 2024 £*
Donations	*398,092*	*17,093*	*415,185*
Grants	*1,996*	*-*	*1,996*
Legacies	*50,000*	*50,000*	*100,000*
Total	*450,088*	*67,093*	*517,181*

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

4 Income from charitable activities

	Unrestricted £	Restricted £	Total 2025 £
365 Income	15,700	-	15,700
Event Income	157,544	-	157,544
Gift Aid	72,370	-	72,370
London Event	76,879	-	76,879
The Big Give	87,682	-	87,682
Other income	621	-	621
Total	410,796	-	410,796

Income from charitable activities - previous year

	Unrestricted £	*Restricted £*	*2024 £*
365 Income	*13,590*	*-*	*13,590*
Event Income	*5,950*	*-*	*5,950*
Gift Aid	*104,716*	*-*	*104,716*
London Event	*72,677*	*-*	*72,677*
MECP2 Fund	*-*	*2,250*	*2,250*
The Big Give	*92,607*	*-*	*92,607*
Other income	*124*	*-*	*124*
Total	*289,664*	*2,250*	*291,914*

5 Cost of raising funds

	2025 £	*2024 £*
Staff costs	194,496	*168,449*
Fundraiser's fees	12,956	*13,470*
365 Prizes	4,891	*3,676*
Event costs	155,759	*112,384*
	368,102	*297,979*

All expenditure on cost of raising funds is unrestricted except for £81,284 of event costs which are restricted (2024:£3,824).

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

6 Analysis of expenditure on charitable activities

	Unrestricted £	Restricted £	Total 2025 £
Staff costs	85,329	-	85,329
Parent 2 Parent programme	37	-	37
CPMRS	24,000	-	24,000
Kings College Grant	112,139	-	112,139
MECP2	-	1,716	1,716
Travel and accommodation	2,084	-	2,084
Governance costs (see note 7)	8,099	-	8,099
Support costs (see note 7)	75,946	-	75,946
	307,634	1,716	309,350

Analysis of expenditure on charitable activities - previous year

	Unrestricted £	*Restricted £*	*2024 £*
Staff costs	*81,884*	*-*	*81,884*
Clinical trial expense	*491*	*3,169*	*3,660*
CPMRS	*36,000*	*-*	*36,000*
Travel and accommodation	*1,886*	*-*	*1,886*
Kings College Grant	*296,583*	*-*	*296,583*
MECP2	*-*	*17,093*	*17,093*
Governance costs (see note 7)	*9,444*	*-*	*9,444*
Support costs (see note 7)	*66,234*	*-*	*66,234*
	492,522	*20,262*	*512,784*

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

7 Analysis of governance and support costs

	Support £	Governance £	Total 2025 £
Accountancy services	18,884	-	18,884
Audit fees	-	4,536	4,536
Legal and professional	3,535	3,563	7,098
Office costs	38,977	-	38,977
Office rental cost	14,550	-	14,550
	75,946	8,099	84,045

Analysis of governance and support costs - previous year

	Support £	*Governance £*	*2024 £*
Accountancy services	*15,794*	*-*	*15,794*
Advertising and marketing	*27*	*-*	*27*
Audit fees	*-*	*4,320*	*4,320*
Legal and professional	*4,525*	*5,124*	*9,649*
Office costs	*32,887*	*-*	*32,887*
Office rental cost	*13,001*	*-*	*13,001*
	66,234	*9,444*	*75,678*

8 Net income/(expenditure) for the year

This is stated after charging/(crediting):	2025 £	*2024 £*
Depreciation	1,208	*1,207*
Auditor's remuneration - audit fees	3,780	*3,400*
Auditor's remuneration - accountancy fees	1,995	*1,850*

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

9 Staff costs

Staff costs during the year were as follows:

	2025 £	*2024* *£*
Wages and salaries	249,878	*221,820*
Social security costs	20,197	*19,642*
Pension costs	9,750	*8,871*
	279,825	*250,333*
Allocated as follows:		
Cost of raising funds	194,496	*168,449*
Charitable activities	85,329	*81,884*
Support costs	-	-
	279,825	*250,333*

One employee has employee benefits in excess of £60,000 (2024: Nil).

The average number of staff employed during the period was 6.4 (2024: 5.3).

The key management personnel of the charity comprise the trustees, the Chief Executive Officer and the Operations Manager. The total employee benefits of the key management personnel of the charity were £132,190 (2024: £114,169).

10 Trustee remuneration and expenses, and related party transactions

Two of the trustees Rachael Stevenson (Chief Executive) and Andrew Stevenson received remuneration totalling £132,471 during the year (2024: £114,169).

Two (three) trustees received travel and subsistence expenses during the year of £717 (2024: £943).

Aggregate donations from related parties were £34,000 (2024: £34,000).

There are no donations from related parties which are outside the normal course of business and no restricted donations from related parties.

The Chief Executive and a director of Reverse Rett, Rachael Stevenson is on the Board of Rett Syndrome Research Trust USA.

Reverse Rett did not make charitable grant to Rett Syndrome USA this year. (2024: £nil).

No trustee or other person related to the charity had any personal interest in any contract or transaction entered into by the charity, including guarantees, during the year (2024: nil).

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

11 Corporation tax

The charity is exempt from tax on income and gains falling within Chapter 3 of Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects. No tax charges have arisen in the charity.

12 Fixed assets: tangible assets

	Computer equipment
Cost	£
At 1 January 2025	12,353
Additions	-
Disposals	-
At 31 December 2025	12,353
Depreciation	
At 1 January 2025	9,938
Charge for the year	1,208
Disposals	-
At 31 December 2025	11,146
Net book value	
At 31 December 2025	1,207
At 31 December 2024	*2,415*

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

13 Debtors

	2025 £	*2024* *£*
Trade debtors	11,047	*600*
Big Give debtor	43,750	*45,000*
Gift aid debtor	6,967	*20,343*
JR Group gala debtor	155,823	-
Prepayments and accrued income	2,908	*26,816*
Other debtors	1,580	*3,645*
	222,075	*96,404*

14 Creditors: amounts falling due within one year

	2025 £	*2024* *£*
Trade creditors	193,840	*218,985*
Taxation and social security costs	8,767	*12,772*
Other creditors and accruals	6,954	*29,183*
	209,561	*260,940*

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

15 Analysis of movements in restricted funds

	Balance at 1 January 2025 £	Income £	Expenditure £	Transfers £	As at 31 December 2025 £
Clinical Research Funds	26,458	-	-	-	26,458
MECP2 Duplication Fund	4,880	-	(1,716)	-	3,164
Rett disorder alliance	4,861	-	-	-	4,861
Reverse Rett LEAP day	-	57,500	(51,484)	-	6,016
Singh Research	30,000	-	(29,800)	-	200
The Fitton Trust	20,000	20,000	(30,133)	-	9,867
Total	86,199	77,500	(113,133)	-	50,566

Previous reporting period	*Balance at 1 January 2024 £*	*Income £*	*Expenditure £*	*Transfers £*	*As at 31 December 2024 £*
Clinical Research Funds	*33,451*	*-*	*(6,993)*	*-*	*26,458*
MECP2 Duplication Fund	*2,630*	*19,343*	*(17,093)*	*-*	*4,880*
Rett disorder alliance	*4,861*	*-*	*-*	*-*	*4,861*
Singh Research	*-*	*30,000*	*-*	*-*	*30,000*
The Fitton Trust	*-*	*20,000*	*-*	*-*	*20,000*
Total	*40,942*	*69,343*	*(24,086)*	*-*	*86,199*

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

15 Analysis of movements in restricted funds continued

Name of	Description, nature and purposes of the fund
Clinical Research Fund	This is a designated fund which will support UK based clinical research and the implementation of treatment for Rett Syndrome and related *MECP2* Disorders in the UK.
MECP2 Duplication Fund (Cure MDS)	The MECP2 Duplication Fund at Reverse Rett is a restricted fund. The fund exclusively supports projects devoted to the study and means of treatment of MECP2 Duplication/Triplication Syndrome. 100% of funds raised and contributed to Reverse Rett by families of children with MECP2 Duplication Syndrome and their supports in the UK are committed to MECP2 Duplication projects via RSRT US.
Rett disorder alliance	This fund relates to collaborative work undertaken through the Rett Disorder Alliance to support shared initiatives aimed at improving awareness, policy and services for people affected by Rett syndrome. No significant activity took place during the year and the remaining balance continues to be held for future collaborative work.
Reverse Rett LEAP Day	Funds were received to support the planning and delivery of the Reverse Rett LEAP Weekend, bringing together families, clinicians and researchers for education, collaboration and peer support. Expenditure during the year related to venue costs, accommodation, travel support and programme delivery, with the remaining balance carried forward to support future LEAP activities.
Singh Research	This fund supports Dr Jatinder Singh's research into pharmacogenomics in Rett syndrome, investigating how CYP2C19, CYP2C9 and CYP2D6 enzyme genotyping may help optimise medication prescribing and improve personalised clinical care for people with Rett syndrome.
The Fitton Trust	Funding from The Fitton Trust supports the development of Reverse Rett's trusts and grants fundraising programme. During the year, the grant enabled fundraising capacity, strengthened grant systems and processes, and supported the development of a sustainable funding pipeline aligned with the charity's long-term strategy.

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

16 Analysis of movement in unrestricted funds

	Balance at 1 January 2025 £	Income £	Expenditure £	Transfers £	As at 31 December 2025 £
General fund	(183,824)	798,282	(564,319)	-	50,139
	(183,824)	798,282	(564,319)	-	50,139

Previous reporting period	*Balance at 1 January 2024 £*	*Income £*	*Expenditure £*	*Transfers £*	*As at 31 December 2024 £*
General fund	*(136,899)*	*739,752*	*(786,677)*	-	*(183,824)*
	(136,899)	*739,752*	*(786,677)*	-	*(183,824)*

Name of unrestricted	**Description, nature and purposes of the fund**
General fund	The free reserves after allowing for all designated funds

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

17 Analysis of net assets between funds

	General fund £	Designated funds £	Restricted funds £	Total £
Tangible fixed assets	1,207	-	-	1,207
Net current assets/(liabilities)	48,932	-	50,566	99,498
Total	50,139	-	50,566	100,705

18 Reconciliation of net movement in funds to net cash flow from operating activities

	2025 £	*2024 £*
Net income/(expenditure) for the year	198,330	*(1,668)*
Adjustments for:		
Depreciation charge	1,208	*1,207*
Decrease/(increase) in debtors	(125,671)	*(55,409)*
Increase/(decrease) in creditors	(51,379)	*75,542*
Net cash provided by/(used in) operating	22,488	*19,672*

Docusign Envelope ID: F7DCED0B-202A-89B1-80BA-98E92E9AA7E8

19 Prior year Statement of Financial Activities (including Income and Expenditure account)

	Unrestricted funds £	Restricted funds £	Total funds 2024 £	*Total funds 2023 £*
Income from:				
Donations and legacies	450,088	67,093	517,181	*454,358*
Charitable activities:	289,664	2,250	291,914	*219,918*
Total income	**739,752**	**69,343**	**809,095**	***674,276***
Expenditure on:				
Raising funds	294,155	3,824	297,979	*228,230*
Charitable activities:	492,522	20,262	512,784	*536,116*
Total expenditure	**786,677**	**24,086**	**810,763**	***764,346***
Net income / (expenditure) for the year	**(46,925)**	**45,257**	**(1,668)**	***(90,070)***
Transfer between funds	-	-	-	-
Net movement in funds for the year	**(46,925)**	**45,257**	**(1,668)**	***(90,070)***
Reconciliation of funds				
Total funds brought forward	(136,899)	40,942	(95,957)	*(5,887)*
Total funds carried forward	**(183,824)**	**86,199**	**(97,625)**	***(95,957)***

The statement of financial activities includes all gains and losses recognised in the year.
All income and expenditure derive from continuing activities.